Vaishali Pharma (VAISHALI) Q2 24/25 earnings summary

Executive summary

• Un-audited financial results for the quarter and half year ended September 30, 2024, were approved by the Board and reviewed by statutory auditors with no material misstatements found.

Financial highlights

• Revenue from operations for Q2 FY25 was ₹2,078.57 lakhs, up from ₹1,256.56 lakhs in Q2 FY24.

• Net profit for Q2 FY25 stood at ₹196.83 lakhs, compared to ₹170.36 lakhs in Q2 FY24.

• EPS for the half year ended September 30, 2024, was ₹2.99 (basic), compared to ₹3.10 for the same period last year.

• Total comprehensive income for H1 FY25 was ₹366.73 lakhs, up from ₹328.96 lakhs in H1 FY24.

Outlook and guidance

• The company continues to operate in a single segment focused on pharmaceutical product sales.